Novartis Raises Sales Forecast for Three Major Drugs to $18 Billion, Expected Annual Growth Rate of 5% by 2031
Novartis has raised the peak sales forecast for three major drugs from $14 billion to $18 billion. The company predicts that the annual sales growth will reach 5% by 2031, slightly down from the previous guidance of 5%-6% until 2030, with a change in the statistical period. Novartis aims to offset the financial impact of patent expirations on older drugs with strong market demand. The combined peak sales of Kesimpta, a treatment for multiple sclerosis, the leukemia drug Scemblix, and the cholesterol-lowering drug Leqvio are expected to reach $18 billion. Novartis's stock fell 2.4% in early trading in Switzerland. Investors are concerned about whether these three drugs can achieve rapid growth amid competition from lower-priced alternatives, compensating for lost revenue. CEO Vas Narasimhan stated that the outlook adjustment considers the expected competition in the U.S. generic drug market for the breast cancer treatment drug Kisqali, which is anticipated to begin in the second half of 2031.
-- Price
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027

Johnson & Johnson Delivered 'Immaculate' Prostate Cancer Data at ESMO. Here's Why Investors Should Care

Real-Life Theranos: New Blood Testing Startup Claims to Predict Health Risks

Sellas Life Sciences Cancer Vaccine Extends Patient Survival in Blood Cancer Clinical Trial

Moderna's Cancer Vaccine Shows Promise, Stock Valuation Raises Concerns

NVIDIA Launches Nemotron for Science to Accelerate Scientific Discoveries with Intelligent Agents

FDA Rejects Approval of Kangfang Biotech's Cancer Drug Ivonescimab

Former Employee Sues Ethereum Foundation, Claims Retaliatory Dismissal After Protesting 'Seppuku' Clause

BRT.Fit Founder Calls for Incorporating Exercise Habits into Cancer Prevention

Nixo sues Ethereum Foundation, Vitalik Buterin over 'suicide pledge' claim

U.S. Senate Rejects Long-Term Regulation Legislation for the Cryptocurrency Industry

Proteomic clocks link accelerated aging to higher risk of death and disease

Aging is not linear: cells go through coordinated stages of deterioration

Trump and Islamophobia: The Chorus That No Longer Mobilizes Votes

Jennifer Tilly Earns Up to $10 Million a Year from The Simpsons Without Ever Participating: Her Story

Bitcoin: Network Power Rises, Profits Disappear

Parliament: Pre-sale of Babak Zanjani's cryptocurrency is illegal; DotOne lacks exchange license

Altria Yields 5.8% and Has Raised Its Dividend 61 Times in 57 Years. Here's Exactly How Much $5,000 Invested Pays Each Year.

Not Lucid. Not Ford. The EV Stock Most Likely to Catch Every Refunded Cybertruck Buyer.

Bitcoin’s $60,000 breakdown puts December Fed decision under the spotlight

The Stock Market Is Doing Something for Only the 5th Time This Century, and History Says It's Obvious What Comes Next for Stocks

Morgan Stanley's Bitcoin Spot ETF MSBT Increases Holdings by 799.212 BTC Against the Trend, Total Holdings Rise to 12,448 BTC

Bitcoin: Poorly Generated Keys Exposed $106 Million to Thieves

Why Is It Difficult for Income Reflows to Boost Cryptocurrency Prices? Net Reflows Are Weakly Correlated with Prices

Peter Schiff says Solana can replace Bitcoin exposure. Can it?

AMD Stock Just Plunged on a Short-Seller Report. Is This a Golden Buying Opportunity?

Why Did Gold Drop Alongside Tech Stocks? It Became the 'ATM' of the Liquidity Crisis

Breaking Down Monad Q3 Report: Transaction-Driven Network Fees, Unlocking Scalable Control

Sky Protocol Faces $2 Billion Stablecoin Redemption!
![[Column] Questions to Consider Regarding the Two-Year Delay in Virtual Asset Taxation... "Where Will It Be Classified?"](/public-static/081_0e4aedee7f.png?format=avif)






